Lymphoma study pulled before it even started

NCT ID NCT07049432

Terminated Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial aimed to test whether the drug N-803 is safe when given as maintenance therapy after CAR T-cell treatment in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-803 (a drug that may boost immune cells)
What this could lead to: If it works, this could point toward a way to improve long-term control of lymphoma after CAR T-cell therapy.
What could go wrong: The trial was withdrawn before any patients were enrolled, so no data exist. It is unknown if N-803 is safe or effective in this setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.